Butyrophenones and sigma-1 receptor antagonists protect against oxidative-stress
AssigneeUniversity of North Texas Health Science Center of Fort Worth
InventorsJohn A. Schetz, James Simpkins, Jeffery Talbert
Life of this patent
Estimating the term…
Abstract
The present invention includes compositions and methods for the protection of one or more central nervous system cells from trauma, when administered before, during or after the trauma, wherein the composition includes an effective amount of a butyrophenone, e.g., a 1-linked phenyl butyrophenone that is electronegative along the butyl chain and/or a Sigma-1 receptor antagonist.
Claims28
1-8. (canceled)
A method for reducing the effect of ischemia comprising contacting cells with a pharmaceutically effective amount of a butyrophenone, wherein the butyrophenone bind to a sigma-1 receptor and protect the cells from the ischemia.
20-28. (canceled)
A method for reducing the effect of ischemia comprising the steps of:
- identifying a patient that will undergo an ischemic interval during surgery;
- and providing the patient a pharmaceutically effective amount of a butyrophenone sufficient to protect the patient from the ischemic interval
36-38. (canceled)
A method for reducing the effect of ischemia comprising contacting one or more cells with a pharmaceutically effective amount of one or more compounds selected from Haloperidol and metabolites thereof in an amount sufficient to protect cells from the ischemia.
40-42. (canceled)
A method of treating a human being suffering from ischemia comprising administering a therapeutically effective amount of a Haloperidol or metabolite thereof wherein the amount is sufficient to protect a cell or tissue from ischemia.
(canceled)
Dependencies are inferred from the claim text.